Xarelto Cerebral Hemorrhage

Xarelto Cerebral Hemorrhage
Patients who use Xarelto may be at risk for a cerebral hemorrhage or other episodes of dangerous, internal bleeding. Thousands of Xarelto lawsuits are now making their way through the courts, all of which allege that the drug’s manufacturers concealed these risks and failed to adequately warn patients and doctors about the complications associated with use of the blood thinning medication.

Xarelto Lawsuit Investigation

The nationwide law firm of Bernstein Liebhard LLP is now investigating potential Xarelto lawsuits on behalf of patients who allegedly suffered cerebral hemorrhage or other bleeding complications related to its use. To learn more, please contact our Firm by calling (888) 994-5118.

Xarelto and Internal Bleeding

Xarelto is a new-generation blood thinner that was launched on the U.S. market in 2011. It is currently approved to prevent strokes in patients with atrial fibrillation; for the prevention of deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee implant surgery; and for the treatment of deep vein thrombosis and pulmonary embolism.

As is the case with warfarin and other blood thinners, Xarelto can sometimes cause a patient to experience serious episodes of internal bleeding. However, there currently exists no approved antidote to reverse Xarelto’s anticoagulant effect should bleeding complications occur. As such, a seemingly-minor trauma can become a life-threatening medical emergency for a Xarelto patient. By comparison, bleeding associated with decades-old warfarin can be stopped via the administration of vitamin K.

What is a Cerebral Hemorrhage?

A cerebral hemorrhage, or brain bleeding, is a type of stroke that occurs when an artery bursts in the brain, resulting in the death of brain cells. Roughly 13% of strokes are caused by cerebral hemorrhage.

Causes of a cerebral hemorrhage may include:

  • Head trauma
  • High blood pressure
  • Aneurysm
  • Blood vessel disorders
  • Amyloid angiopathy
  • Blood or bleeding disorders
  • Liver disease
  • Brain disorders

Symptoms of a cerebral hemorrhage may include:

  • Sudden severe headache
  • Unexplained seizures
  • Weakness in an arm or leg
  • Nausea or vomiting
  • Decreased alertness; lethargy
  • Vision changes
  • Tingling or numbness
  • Difficulty with speaking, understanding speech, writing or reading
  • Difficulty swallowing
  • Loss of fine motor skills
  • Loss of coordination
  • Loss of balance
  • An abnormal sense of taste
  • Loss of consciousness

Occurrence of Brain Bleed with Xarelto

The ROCKET AF study, a two-year clinical trial involving 14,000 patients, reported the following adverse events among Xarelto patients:

  • 172 patients (0.68% per year) suffered intracranial hemorrhage
  • 74% of brain bleeds were intracerebral hemorrhage
  • Subarachnoid hemorrhage, subdural hemorrhage, and extradural hemorrhage was also reported among Xarelto patients.

The ROCKET AF clinical trial played an important role in Xarelto’s regulatory approval, both in the U.S. and abroad.

Xarelto Lawsuit Developments

  • January 2016: The federal Xarelto litigation convened a Status Conference on January 22nd, at which time it scheduled Oral Arguments for February 23rd regarding  a proposed order governing the parties’ interactions with plaintiffs’ prescribing and treating physicians. It was also noted that the parties exchanged bellwether trial selections on January 11th, while random selections were made on January 15th. Read More
  • December 2015: The federal court overseeing thousands of Xarelto lawsuits has instituted procedures governing bellwether trial selection. Two trials will get underway in the U.S. District Court, Eastern District of Louisiana, on February 6, 2017 and March 13, 2017. The third and fourth will take place in yet-to-be determined Districts in Mississippi and Texas on April 24, 2017 and May 30, 2017. Read More
  • April 2015: The federal Xarelto litigation is to convene “Science Day” on June 28th, 2015.Read More
  • December 2014: The U.S. Judicial Panel on Multidistrict Litigation (JPML) has established multidistrict litigation for federally-filed Xarelto bleeding claims in the U.S. District Court, Eastern District of Louisiana. Read More
  • October 2014: Six Plaintiffs in Xarelto lawsuits file a motion seeking centralization of all such federal claims in a single court for the purposes of coordinated pretrial proceedings. Read More

Legal Help for Victims of Xarelto Cerebral Hemorrhage

The defective drug attorneys at Bernstein Liebhard LLP are providing free, no-obligation legal reviews to alleged victims of Xarelto-related cerebral hemorrhage. To obtain your case review, please call (888) 994-5118.

  1. Xarelto (rivaroxaban) U.S. Food and Drug Administration (November 2012) http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm326654.htm
  2. NEJM (2011) “Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation” http://www.nejm.org/doi/full/10.1056/NEJMoa1009638
Last Modified: February 23, 2016

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us

RXInjuryHelp.com on Google+  RXInjuryHelp.com on Facebook  RXInjuryHelp.com on LinkedIn  RXInjuryHelp.com on Twitter  RXInjuryHelp.com on YouTube  RXInjuryHelp.com on Pinterest